A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Autor: Clamp, A.R., Blackhall, F., Vasey, P., Soukop, M., Coleman, R., Halbert, G., Robson, L., Jayson, G.C., Canc Res UK Phase I II Comm
Jazyk: angličtina
Rok vydání: 2003
ISSN: 0007-0920
Popis: Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.
Databáze: OpenAIRE